Literature DB >> 9399612

Cost analysis of the American College of Chest Physicians guidelines for deep vein thrombosis prophylaxis in patients undergoing orthopedic arthroplastic surgery.

W E Wade1, W J Spruill.   

Abstract

Guidelines for prophylaxis of deep vein thrombosis secondary to orthopedic surgery have been developed. In selecting a specific drug for formulary inclusion, it is ideal for an individual institution to determine the cost of therapy, as well as the frequency of adverse events and the cost of treating them for each agent undergoing consideration. Cost-effectiveness analysis using incremental cost-effectiveness ratios and sensitivity analyses are useful for determining which drug may be most cost effective.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9399612

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  3 in total

Review 1.  Formulary management of low molecular weight heparins.

Authors:  W E Wade; B C Martin; J A Kotzan; W J Spruill; M A Chisoholm; M Perri
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

Review 2.  Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.

Authors:  Alok Kapoor; Warren Chuang; Nila Radhakrishnan; Kenneth J Smith; Dan Berlowitz; Jodi B Segal; Jeffrey N Katz; Elena Losina
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Hospital-based costs associated with venous thromboembolism prophylaxis regimens.

Authors:  Geno Merli; Cheryl P Ferrufino; Jay Lin; Mohammed Hussein; David Battleman
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.